JP2018527295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527295A5 JP2018527295A5 JP2017566161A JP2017566161A JP2018527295A5 JP 2018527295 A5 JP2018527295 A5 JP 2018527295A5 JP 2017566161 A JP2017566161 A JP 2017566161A JP 2017566161 A JP2017566161 A JP 2017566161A JP 2018527295 A5 JP2018527295 A5 JP 2018527295A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ring
- atom
- substituted
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 101150109738 Ptger4 gene Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 150000001924 cycloalkanes Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000007474 aortic aneurysm Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- -1 5-tetrazolyl Chemical group 0.000 claims 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 1
- WBGYLVWDBOGTNU-INIZCTEOSA-N COc1ccc(CN2CCOc3ccnc(N[C@@H](C)c4ccc(cc4)C(O)=O)c23)cc1 Chemical compound COc1ccc(CN2CCOc3ccnc(N[C@@H](C)c4ccc(cc4)C(O)=O)c23)cc1 WBGYLVWDBOGTNU-INIZCTEOSA-N 0.000 claims 1
- ABPSJACXBSUUTJ-HNNXBMFYSA-N C[C@H](Nc1nccc2OCCN(Cc3cccc(Cl)c3)c12)c1ccc(cc1)C(O)=O Chemical compound C[C@H](Nc1nccc2OCCN(Cc3cccc(Cl)c3)c12)c1ccc(cc1)C(O)=O ABPSJACXBSUUTJ-HNNXBMFYSA-N 0.000 claims 1
- AMGKUSVGMAGQLE-UHFFFAOYSA-N FC=1C=C(C=CC=1F)CN1C2=C(OCC1)C=CN=C2NC1(CC1)C1=CC=C(C(=O)O)C=C1 Chemical compound FC=1C=C(C=CC=1F)CN1C2=C(OCC1)C=CN=C2NC1(CC1)C1=CC=C(C(=O)O)C=C1 AMGKUSVGMAGQLE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2244/DEL/2015 | 2015-07-23 | ||
| IN2244DE2015 | 2015-07-23 | ||
| PCT/JP2016/072244 WO2017014323A1 (en) | 2015-07-23 | 2016-07-22 | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527295A JP2018527295A (ja) | 2018-09-20 |
| JP2018527295A5 true JP2018527295A5 (enExample) | 2019-06-13 |
| JP6689297B2 JP6689297B2 (ja) | 2020-04-28 |
Family
ID=56740432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566161A Expired - Fee Related JP6689297B2 (ja) | 2015-07-23 | 2016-07-22 | 複素環化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10745397B2 (enExample) |
| EP (1) | EP3325490B1 (enExample) |
| JP (1) | JP6689297B2 (enExample) |
| CN (1) | CN108368127B (enExample) |
| CA (1) | CA2993312A1 (enExample) |
| DK (1) | DK3325490T3 (enExample) |
| WO (1) | WO2017014323A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| SG11201908660RA (en) | 2017-05-18 | 2019-10-30 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| CA3060597A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| AR111874A1 (es) | 2017-05-18 | 2019-08-28 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| WO2019147987A1 (en) * | 2018-01-26 | 2019-08-01 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Antimicrobial compositions and methods of using the same |
| JP2021513512A (ja) * | 2018-02-05 | 2021-05-27 | シェンチェン イオノヴァ ライフ サイエンス カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｉｏｎｏｖａ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． | 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸 |
| MX2021004735A (es) | 2018-10-23 | 2021-06-04 | Basf Se | Compuestos plaguicidas triciclicos. |
| MX2021010323A (es) * | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
| CN112094249B (zh) * | 2019-06-17 | 2022-03-08 | 中国科学院苏州纳米技术与纳米仿生研究所 | 磺胺甲噻二唑-糖精共晶及其制备方法与应用 |
| CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
| WO2021209265A1 (en) | 2020-04-14 | 2021-10-21 | Basf Se | Tricyclic pesticidal compounds |
| EP3907214A1 (en) * | 2020-05-04 | 2021-11-10 | Dompe' Farmaceutici S.P.A. | Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834468A (en) * | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| DE19944767A1 (de) * | 1999-09-17 | 2001-03-29 | Vasopharm Biotech Gmbh & Co Kg | N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2001032632A2 (en) | 1999-11-01 | 2001-05-10 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
| ATE527258T1 (de) | 2004-07-28 | 2011-10-15 | Takeda Pharmaceutical | Pyrroloä2,3-cüpyridinverbindung, verfahren zu deren herstellung und anwendung |
| EP1828186A1 (en) | 2004-12-13 | 2007-09-05 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| TW200838526A (en) * | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
| WO2008123963A1 (en) * | 2007-04-02 | 2008-10-16 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| WO2009005076A1 (ja) * | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| DK2565191T3 (da) * | 2008-05-14 | 2014-11-10 | Astellas Pharma Inc | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati |
| US8404736B2 (en) * | 2008-08-14 | 2013-03-26 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as EP4 receptor antagonists |
| US20110172217A1 (en) * | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| JP5683489B2 (ja) | 2009-01-12 | 2015-03-11 | アレイ バイオファーマ、インコーポレイテッド | ピペリジン含有化合物およびその用途 |
| AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| KR101911105B1 (ko) | 2010-09-21 | 2018-10-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 제약 조성물 |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| WO2016088903A1 (en) | 2014-12-05 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
-
2016
- 2016-07-22 JP JP2017566161A patent/JP6689297B2/ja not_active Expired - Fee Related
- 2016-07-22 WO PCT/JP2016/072244 patent/WO2017014323A1/en not_active Ceased
- 2016-07-22 EP EP16753995.6A patent/EP3325490B1/en active Active
- 2016-07-22 DK DK16753995.6T patent/DK3325490T3/da active
- 2016-07-22 CA CA2993312A patent/CA2993312A1/en not_active Abandoned
- 2016-07-22 CN CN201680042838.4A patent/CN108368127B/zh not_active Expired - Fee Related
- 2016-07-26 US US15/746,828 patent/US10745397B2/en not_active Expired - Fee Related
-
2020
- 2020-07-06 US US16/921,338 patent/US20200339577A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527295A5 (enExample) | ||
| JP2016531950A5 (ja) | 複素環化合物 | |
| JP2016516043A5 (enExample) | ||
| JP2013510125A5 (enExample) | ||
| JP2011132222A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2015517976A5 (enExample) | ||
| JP2014514360A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2014525438A5 (enExample) | ||
| JP2012532136A5 (enExample) | ||
| JP2017525668A5 (enExample) | ||
| JP2013528204A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2016516699A5 (enExample) | ||
| PE20090596A1 (es) | Imidazoles biciclicos fusionados | |
| JP2014500295A5 (enExample) | ||
| JP2015504076A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2017509689A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2017538689A5 (enExample) | ||
| JP2014509600A5 (enExample) |